JP7305664B2 - タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 - Google Patents
タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 Download PDFInfo
- Publication number
- JP7305664B2 JP7305664B2 JP2020545293A JP2020545293A JP7305664B2 JP 7305664 B2 JP7305664 B2 JP 7305664B2 JP 2020545293 A JP2020545293 A JP 2020545293A JP 2020545293 A JP2020545293 A JP 2020545293A JP 7305664 B2 JP7305664 B2 JP 7305664B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- compound
- haloc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637147P | 2018-03-01 | 2018-03-01 | |
| US62/637,147 | 2018-03-01 | ||
| PCT/US2019/020395 WO2019169326A1 (en) | 2018-03-01 | 2019-03-01 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514999A JP2021514999A (ja) | 2021-06-17 |
| JP2021514999A5 JP2021514999A5 (cg-RX-API-DMAC7.html) | 2022-02-17 |
| JP7305664B2 true JP7305664B2 (ja) | 2023-07-10 |
Family
ID=67767960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545293A Active JP7305664B2 (ja) | 2018-03-01 | 2019-03-01 | タンパク質アルギニンメチルトランスフェラーゼの阻害剤としてのエタンジアミン-複素環誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11028083B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3758698A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7305664B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867584A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019226585A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017541A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092579A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019169326A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
| WO2022192527A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004149429A (ja) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20140315904A1 (en) | 2013-03-14 | 2014-10-23 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
| US9593109B2 (en) * | 2011-08-26 | 2017-03-14 | Cymabay Therapeutics, Inc. | Bicyclic agonists of GPR131 and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9133189B2 (en) * | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| CA2903394C (en) * | 2013-03-14 | 2021-08-31 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
| EP2970181B1 (en) * | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US20170283400A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
| WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
| KR102148587B1 (ko) | 2016-02-23 | 2020-08-26 | 화이자 인코포레이티드 | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 |
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
-
2019
- 2019-03-01 BR BR112020017541-2A patent/BR112020017541A2/pt not_active Application Discontinuation
- 2019-03-01 JP JP2020545293A patent/JP7305664B2/ja active Active
- 2019-03-01 WO PCT/US2019/020395 patent/WO2019169326A1/en not_active Ceased
- 2019-03-01 CA CA3092579A patent/CA3092579A1/en active Pending
- 2019-03-01 CN CN201980020505.5A patent/CN111867584A/zh active Pending
- 2019-03-01 US US16/290,675 patent/US11028083B2/en not_active Expired - Fee Related
- 2019-03-01 AU AU2019226585A patent/AU2019226585A1/en not_active Abandoned
- 2019-03-01 EP EP19761558.6A patent/EP3758698A4/en not_active Withdrawn
-
2021
- 2021-05-04 US US17/307,568 patent/US11725008B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004149429A (ja) | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20140315904A1 (en) | 2013-03-14 | 2014-10-23 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017541A2 (pt) | 2020-12-22 |
| EP3758698A1 (en) | 2021-01-06 |
| WO2019169326A1 (en) | 2019-09-06 |
| CN111867584A (zh) | 2020-10-30 |
| US11028083B2 (en) | 2021-06-08 |
| US20190270739A1 (en) | 2019-09-05 |
| CA3092579A1 (en) | 2019-09-06 |
| AU2019226585A1 (en) | 2020-10-08 |
| US20230027126A1 (en) | 2023-01-26 |
| EP3758698A4 (en) | 2021-10-20 |
| US11725008B2 (en) | 2023-08-15 |
| JP2021514999A (ja) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019263294B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
| US12186324B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| AU2017371084A1 (en) | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | |
| WO2009032754A2 (en) | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease | |
| US20190308978A1 (en) | Imidazopiperazinone inhibitors of transcription activating proteins | |
| WO2021108198A1 (en) | Inhibitors of receptor interacting protein kinase i for the treatment of disease | |
| AU2021355480B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| US20180057507A1 (en) | Inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease | |
| JP2022553273A (ja) | 疾患の治療のための二重ロイシンジッパー(dlk)キナーゼのビシクロ[1.1.1]ペンタン阻害剤 | |
| US11725008B2 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| WO2022192527A1 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| WO2026072966A2 (en) | Pi3k degrader compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220208 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230512 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230628 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7305664 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |